International Journal of Cardiovascular Sciences. 17/Jun/2021;34(5):566-9.
Kawasaki-Like Disease, a New Phenotype in Sars-CoV-2?
Beatriz Sordi Chara
, Júlia Machado Rickli
, Caroline Figueiredo da Silva
, Gabriela Pomaleski
, Rafael de March Ronsoni
, Marcus Vinícius Magno Gonçalves
Abstract
The coronavirus disease (COVID-19), that assumed pandemic proportions in March 2020, mainly affects the respiratory tract, causing severe interstitial pneumonia in adults. Worldwide data indicate that COVID-19 tends to be more benign in children, which is evidenced by a high incidence of asymptomatic or mild upper airways’ infection cases in this population. However, recent studies have been associating Kawasaki-like symptoms as a nonclassical presentation of coronavirus disease in pediatrics. It is suggested that the intense cytokine cascade, promoted by the SARS-CoV-2 infection, can trigger a multisystem inflammatory response as an atypical Kawasaki form in genetically predisposed individuals. In this context, patients may develop more severe clinical features with a greater predisposition to myocardial involvement, Macrophage Activation Syndrome, and Kawasaki Disease Shock Syndrome. Despite critical conditions, patients usually respond to conventional treatment of Kawasaki Disease with intravenous immunoglobulin. This article intends to provide an approach to the association between Kawasaki-Like Syndrome and COVID-19.
1,245
